Faeth Therapeutics (FTH) Accounts Payables (2020 - 2026)
Faeth Therapeutics' (FTH) quarterly Accounts Payables came in at $9.0 million in Q1 2026, up 280.92% YoY from $2.4 million in Q1 2025, and up 1203.63% on a QoQ basis from $689000.0 in Q4 2025.
Faeth Therapeutics (FTH) Accounts Payables (2020 - 2026) Analysis & Trends
Faeth Therapeutics (FTH) has 7 years of Accounts Payables data on file, last reported at $9.0 million in Q1 2026.
- Quarterly Accounts Payables rose 280.92% year-over-year to $9.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.0 million (up 280.92% YoY) and the FY2025 annual result came in at $689000.0, down 44.79% from the prior year.
- Accounts Payables rose to $9.0 million in Q1 2026, from $689000.0 in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $9.0 million in Q1 2026 to a low of $351000.0 in Q2 2025.
- A 5-year average of $2.8 million and a median of $2.3 million in 2023 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2023 — Accounts Payables slumped 87.19% — and 2026, when it surged 280.92%.
- Tracing FTH's Accounts Payables over 5 years: stood at $4.5 million in 2022, then tumbled by 87.19% to $573000.0 in 2023, then soared by 117.8% to $1.2 million in 2024, then tumbled by 44.79% to $689000.0 in 2025, then jumped by 1203.63% to $9.0 million in 2026.
- The last three Accounts Payables figures came in at $9.0 million (Q1 2026), $689000.0 (Q4 2025), and $1.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.57 Bn | 131.72 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 86.71 Bn | 78.72 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 65.44 Bn | 60.25 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 60.06 Bn | 54.93 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.89 Bn | 28.58 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.11 Bn | 9.72 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.59 Bn | 26.43 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 35.57 Mn |
| 10 | Faeth Therapeutics | 186.06 Mn | 186.06 Mn | - | 7.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.57 Mn |
| Mar 31, 2026 | 8.98 Mn |
| Dec 31, 2025 | 689,000.00 |
| Sep 30, 2025 | 1.41 Mn |
| Jun 30, 2025 | 351,000.00 |
| Mar 31, 2025 | 2.36 Mn |
| Dec 31, 2024 | 1.25 Mn |
| Sep 30, 2024 | 1.68 Mn |
| Jun 30, 2024 | 1.65 Mn |
| Mar 31, 2024 | 2.00 Mn |
| Dec 31, 2023 | 573,000.00 |
| Sep 30, 2023 | 2.73 Mn |
| Jun 30, 2023 | 2.33 Mn |
| Mar 31, 2023 | 4.72 Mn |
| Dec 31, 2022 | 4.47 Mn |
| Sep 30, 2022 | 4.66 Mn |
| Jun 30, 2022 | 2.42 Mn |
| Mar 31, 2022 | 5.10 Mn |
| Dec 31, 2021 | 2.46 Mn |
| Sep 30, 2021 | 3.61 Mn |